BR112019023552A2 - Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina - Google Patents
Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina Download PDFInfo
- Publication number
- BR112019023552A2 BR112019023552A2 BR112019023552-3A BR112019023552A BR112019023552A2 BR 112019023552 A2 BR112019023552 A2 BR 112019023552A2 BR 112019023552 A BR112019023552 A BR 112019023552A BR 112019023552 A2 BR112019023552 A2 BR 112019023552A2
- Authority
- BR
- Brazil
- Prior art keywords
- dementia
- disease
- lewy bodies
- test
- pharmaceutically acceptable
- Prior art date
Links
- CKJDCNZBABIEBZ-HNNXBMFYSA-N Cc(c(-c(cc1)cc(N2)c1-c([n]([C@@H]1COCC1)nc1)c1C2=O)c1C)cnc1OC Chemical compound Cc(c(-c(cc1)cc(N2)c1-c([n]([C@@H]1COCC1)nc1)c1C2=O)c1C)cnc1OC CKJDCNZBABIEBZ-HNNXBMFYSA-N 0.000 description 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762513727P | 2017-06-01 | 2017-06-01 | |
| US62/513.727 | 2017-06-01 | ||
| PCT/JP2018/020650 WO2018221551A1 (ja) | 2017-06-01 | 2018-05-30 | ピラゾロキノリン誘導体を含有するレビー小体病治療剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112019023552A2 true BR112019023552A2 (pt) | 2020-06-02 |
Family
ID=64456542
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112019023552-3A BR112019023552A2 (pt) | 2017-06-01 | 2018-05-30 | Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11311530B2 (https=) |
| EP (1) | EP3632438B1 (https=) |
| JP (1) | JP7269875B2 (https=) |
| KR (1) | KR20200010220A (https=) |
| CN (1) | CN110612102A (https=) |
| AU (1) | AU2018278422B2 (https=) |
| BR (1) | BR112019023552A2 (https=) |
| CA (1) | CA3061884A1 (https=) |
| ES (1) | ES2961554T3 (https=) |
| IL (1) | IL270357B2 (https=) |
| MX (1) | MX394435B (https=) |
| TW (1) | TWI784006B (https=) |
| WO (1) | WO2018221551A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018221550A1 (ja) | 2017-06-01 | 2018-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
| RU2019135834A (ru) | 2017-06-01 | 2021-07-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила |
| KR20200010211A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Pde9 저해제를 포함하는 약제학적 조성물 |
| WO2023064857A1 (en) | 2021-10-14 | 2023-04-20 | Incyte Corporation | Quinoline compounds as inhibitors of kras |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5318759A (en) | 1976-08-02 | 1978-02-21 | Nisshin Oil Mills Ltd | Method of making fried beancurd |
| JPH05132484A (ja) | 1991-04-26 | 1993-05-28 | Otsuka Pharmaceut Factory Inc | ピラゾロキノリン及びピラゾロナフチリジン誘導体 |
| DK0760819T3 (da) | 1994-05-24 | 2000-10-09 | Hoffmann La Roche | Tricykliske dicarbonylderivater |
| DE19642591A1 (de) | 1996-10-15 | 1998-04-16 | Basf Ag | Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung |
| HN2002000317A (es) | 2001-11-02 | 2003-05-21 | Pfizer | Inhibidores de pde9 para tratamiento de trastornos cardiovasculares |
| BR0313262A (pt) | 2002-08-07 | 2005-07-12 | Mitsubishi Pharma Corp | Compostos de dihidropirazolpiridina |
| DE10238722A1 (de) * | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
| DE102004004142A1 (de) | 2003-05-09 | 2004-11-25 | Bayer Healthcare Ag | 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine |
| RU2426734C2 (ru) | 2003-10-03 | 2011-08-20 | Зм Инновейтив Пропертиз Компани | Пиразолопиридины и их аналоги |
| WO2005118583A1 (en) | 2004-05-28 | 2005-12-15 | Millennium Pharmaceuticals, Inc. | 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors |
| JP2006045118A (ja) | 2004-08-04 | 2006-02-16 | Mochida Pharmaceut Co Ltd | 新規ピラゾロキノロン誘導体 |
| CA2622605A1 (en) | 2005-09-15 | 2007-03-22 | Aska Pharmaceutical Co., Ltd. | Heterocycle compound, and production process and application thereof |
| CA2671980C (en) | 2006-12-13 | 2015-05-05 | Aska Pharmaceutical Co., Ltd. | Quinoxaline derivatives |
| WO2008072778A1 (ja) | 2006-12-13 | 2008-06-19 | Aska Pharmaceutical Co., Ltd. | 尿路系疾患の処置剤 |
| PT2152712E (pt) | 2007-05-11 | 2012-02-29 | Pfizer | Compostos amino-heterocíclicos |
| UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
| JP5453431B2 (ja) | 2008-09-08 | 2014-03-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用 |
| TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基－雜環化合物 |
| WO2010101230A1 (ja) | 2009-03-05 | 2010-09-10 | アステラス製薬株式会社 | キノキサリン化合物 |
| PE20120505A1 (es) | 2009-03-31 | 2012-05-09 | Boehringer Ingelheim Int | Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a |
| US8880976B2 (en) | 2009-09-25 | 2014-11-04 | Stmicroelectronics, Inc. | Method and apparatus for encoding LBA information into the parity of a LDPC system |
| AP2012006631A0 (en) | 2010-08-12 | 2012-12-31 | Boehringer Ingelheim Int | 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors |
| RS54834B1 (sr) | 2010-09-07 | 2016-10-31 | Astellas Pharma Inc | Jedinjenja pirazolokvinolina |
| US20130040971A1 (en) | 2011-02-14 | 2013-02-14 | Boehringer Ingelheim International Gmbh | 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders |
| PT2573073E (pt) | 2011-09-26 | 2015-02-05 | Sanofi Sa | Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica |
| JP6042060B2 (ja) | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
| WO2013051639A1 (ja) | 2011-10-07 | 2013-04-11 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体 |
| TW201439091A (zh) | 2013-04-05 | 2014-10-16 | Eisai R&D Man Co Ltd | 吡啶基吡唑并喹啉化合物 |
| EP2982675B1 (en) * | 2013-04-05 | 2017-08-16 | Eisai R&D Management Co., Ltd. | Salt of pyrazoloquinoline derivative, and crystal thereof |
| KR20200010211A (ko) | 2017-06-01 | 2020-01-30 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Pde9 저해제를 포함하는 약제학적 조성물 |
| RU2019135834A (ru) | 2017-06-01 | 2021-07-13 | Эйсай Ар Энд Ди Менеджмент Ко., Лтд. | Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила |
| WO2018221550A1 (ja) | 2017-06-01 | 2018-12-06 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤 |
-
2018
- 2018-05-30 BR BR112019023552-3A patent/BR112019023552A2/pt not_active IP Right Cessation
- 2018-05-30 KR KR1020197033124A patent/KR20200010220A/ko not_active Ceased
- 2018-05-30 JP JP2019521251A patent/JP7269875B2/ja active Active
- 2018-05-30 TW TW107118423A patent/TWI784006B/zh active
- 2018-05-30 CN CN201880030146.7A patent/CN110612102A/zh active Pending
- 2018-05-30 WO PCT/JP2018/020650 patent/WO2018221551A1/ja not_active Ceased
- 2018-05-30 IL IL270357A patent/IL270357B2/en unknown
- 2018-05-30 EP EP18810202.4A patent/EP3632438B1/en active Active
- 2018-05-30 CA CA3061884A patent/CA3061884A1/en active Pending
- 2018-05-30 US US16/611,374 patent/US11311530B2/en active Active
- 2018-05-30 MX MX2019013397A patent/MX394435B/es unknown
- 2018-05-30 AU AU2018278422A patent/AU2018278422B2/en active Active
- 2018-05-30 ES ES18810202T patent/ES2961554T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| ES2961554T3 (es) | 2024-03-12 |
| IL270357A (https=) | 2020-02-27 |
| US11311530B2 (en) | 2022-04-26 |
| IL270357B2 (en) | 2024-02-01 |
| TW201902479A (zh) | 2019-01-16 |
| EP3632438B1 (en) | 2023-08-23 |
| JP7269875B2 (ja) | 2023-05-09 |
| AU2018278422B2 (en) | 2022-03-17 |
| MX394435B (es) | 2025-03-12 |
| RU2019135690A (ru) | 2021-07-13 |
| EP3632438A4 (en) | 2020-12-23 |
| MX2019013397A (es) | 2020-02-07 |
| AU2018278422A1 (en) | 2019-11-21 |
| WO2018221551A1 (ja) | 2018-12-06 |
| IL270357B1 (en) | 2023-10-01 |
| TWI784006B (zh) | 2022-11-21 |
| JPWO2018221551A1 (ja) | 2020-04-02 |
| CN110612102A (zh) | 2019-12-24 |
| KR20200010220A (ko) | 2020-01-30 |
| CA3061884A1 (en) | 2019-10-29 |
| RU2019135690A3 (https=) | 2021-08-25 |
| US20200155541A1 (en) | 2020-05-21 |
| EP3632438A1 (en) | 2020-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2938546T3 (es) | Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina | |
| Baarendse et al. | Differential involvement of the dorsal hippocampus in passive avoidance in C57bl/6J and DBA/2J mice | |
| BR112019023569A2 (pt) | Agente terapêutico da demência combinando derivados de pirazoloquinolina e donepezila | |
| Harrison et al. | Neurorestoration induced by the HDAC inhibitor sodium valproate in the lactacystin model of P arkinson's is associated with histone acetylation and up‐regulation of neurotrophic factors | |
| ES2673016T3 (es) | Tratamiento de los síntomas negativos de la esquizofrenia con (R)-7-cloro-N-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida y sales farmacéuticamente aceptables de la misma | |
| BR112019023552A2 (pt) | Agente terapêutico para a demência com corpos de lewy contendo derivado de pirazoloquinolina | |
| Anand et al. | The animal models of dementia and Alzheimer’s disease for pre-clinical testing and clinical translation | |
| ES2985184T3 (es) | Agente terapéutico para la demencia que combina derivado de pirazoloquinolina y memantina | |
| EA037187B1 (ru) | Способ и композиция для лечения когнитивного расстройства | |
| Trenkwalder et al. | Pain, opioids, and sleep: implications for restless legs syndrome treatment | |
| BR112019015000A2 (pt) | uso de pridopidina para o tratamento da síndrome do x frágil | |
| Liu et al. | Activation and blockade of serotonin6 receptors in the dorsal hippocampus enhance T maze and hole-board performance in a unilateral 6-hydroxydopamine rat model of Parkinson's disease | |
| Grafman | Neuronal plasticity: Building a bridge from the laboratory to the clinic | |
| US10071107B2 (en) | Pharmaceutical composition for prevention, treatment or delay of Alzheimer's disease or dementia containing G protein-coupled receptor 19 agent as active ingredient | |
| Desai et al. | Pharmacological characterization of a dopamine transporter ligand that functions as a cocaine antagonist | |
| Shin et al. | BT‐11 improves stress‐induced memory impairments through increment of glucose utilization and total neural cell adhesion molecule levels in rat brains | |
| Kleitz‐Nelson et al. | Differential effects of central injections of D1 and D2 receptor agonists and antagonists on male sexual behavior in Japanese quail | |
| WO2015060746A1 (ru) | Комбинация для лечения и/или профилактики проявлений психических, когнитивных, поведенческих и неврологических нарушений при органических заболеваниях цнс различного генеза | |
| Nazari-Serenjeh et al. | Blocking the dopaminergic receptors within the hippocampal dentate gyrus reduced analgesic responses induced by restraint stress in the formalin test | |
| CN101678010B (zh) | 包含(R)-螺[1-氮杂二环[2.2.2]辛烷-3,2’(3’H)-呋喃并[2,3-b]吡啶](AZD0328)的组合物及其在制备治疗阿耳茨海默氏病、ADHD和认知功能障碍的药物中的用途 | |
| BR112021005932A2 (pt) | composição farmacêutica, combinação farmacêutica neuroprotetora, inibidor da acetilcolinesterase e agonista receptor de 5-ht4 | |
| Charron et al. | In vivo administration of corticotropin-releasing hormone at remote intervals following ischemia enhances CA1 neuronal survival and recovery of spatial memory impairments: a role for opioid receptors | |
| RU2802212C2 (ru) | Терапевтическое средство для лечения болезни телец леви, содержащее производное пиразолохинолина | |
| Ardayfio et al. | Pitx3-deficient aphakia mice display unique behavioral responses to psychostimulant and antipsychotic drugs | |
| BRPI0611204A2 (pt) | mÉtodo para o tratamento e prevenÇço de fobia de barulho em animal de companhia; e composiÇço veterinÁria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2830 DE 01-04-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |